ubs glp-1 sales forecast Beyond GLP-1Rs: emerging targets poised to gain share of obesity market GLP-1 Receptor Agonist Market Size

ASC39 is an oral amylin receptor agonist

The companys higher-dose version of Wegovy won FDA approval Thursday, based on trial results showing average weight loss of 21% over 72 weeks, putting it in the same league as Lillys Zepbound

PHILADELPHIA (WPVI) -- GLP-1 medications remain one of the most popular weight loss drugs on the market, but new research suggests consistency may be key to maintaining their effectiveness

Cost effectiveness: healthy eating, activity, small behavior changes are usually much less expensiveand more within peoples control

report no conflicts of interest

Louis Aronne, director of comprehensive weight control center, Weill Cornell Medicine